HER2 status assessment in carcinomas of various localizations. A multicenter morphological study in the Russian Federation
- 18 June 2026
- journal article
- research article
- Published by Media Sphere Publishing Group in Russian Journal of Archive of Pathology
- Vol. 88 (3) , 7-14
Abstract
HER2 is a clinically significant predictive and prognostic marker in a number of epithelial malignant neoplasms. With the introduction of HER2-targeted therapeutic approaches, including antibody-drug conjugates, the need for standardized assessment of HER2 status in tumors of various localizations has become increasingly important. Objective. To assess the prevalence of HER2-positive tumors (IHC 3+) in epithelial malignant neoplasms of various localizations in the Russian population using a unified diagnostic approach. Material and methods. This multicenter study included 1.511 tumor tissue samples from patients with epithelial malignant neoplasms of various localizations, obtained from reference pathology centers of the Russian Federation. HER2 status was determined by immunohistochemistry using anti-HER2 antibody (clone 4B5, Ventana) and standardized interpretation criteria developed for gastric cancer and gastroesophageal junction cancer. In cases of equivocal HER2 status (IHC 2+), in situ hybridization was recommended. Results. HER2-positive tumors (IHC 3+) were identified in the majority of the analyzed localizations, with prevalence varying widely depending on tumor type. The highest frequency of HER2 positivity was observed in urothelial carcinoma of the urinary bladder, as well as in gastric and gastroesophageal junction cancers. No HER2-positive cases were detected in lung adenocarcinoma or pancreatic cancer. Conclusion. The study results confirm the reproducibility of HER2 status assessment using a unified diagnostic approach in a multicenter setting. The application of standardized HER2 interpretation criteria ensures data comparability and provides a methodological basis for further clinicopathological studies and for the implementation of HER2-targeted therapeutic strategies in clinical practice.Keywords
This publication has 7 references indexed in Scilit:
- Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trialThe Lancet Oncology, 2024
- Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II TrialJournal of Clinical Oncology, 2024
- Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 TrialJournal of Clinical Oncology, 2023
- Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerArchives of Pathology & Laboratory Medicine, 2023
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused UpdateJournal of Clinical Oncology, 2018
- HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical OncologyArchives of Pathology & Laboratory Medicine, 2016
- The Product of the Human c- erb B-2 Gene: a 185-Kilodalton Glycoprotein with Tyrosine Kinase ActivityScience, 1986